Bone Therapeutics SA announced the closing of its acquisition of a majority participation in Medsenic. The ESM has also approved the name change of Bone Therapeutics into BioSenic. The BioSenic' ESM also approved the appointment of a new board, consisting of a total of up to seven directors including Jean Stéphenne and Jean-Luc Vandebroek that are transitioning to the Biosenic Board, while all other Bone Therapeutics Board directors have terminated their mandate.

Pr. Francois Rieger, chairman and CEO of Medsenic, has been appointed as chairman and CEO of BioSenic SA. Other board members are Ms Véronique Pomi-Schneiter, deputy CEO of Biosenic, formerly in charge of Medsenic operations, Mr. Jean-François Rax, representing Cap Innovest, Ms Revital Rattenbach, independent director and Mr. Terry Sadler, independent director.

The Executive leadership team now consists of François Rieger (CEO), Véronique Pomi-Schneiter (deputy CEO), and Anne Leselbaum (CMO).